Tannic acid
Depinar (tannic acid) is an unknown pharmaceutical. Tannic acid was first approved as Depinar on 1982-01-01. It is known to target anoctamin-1.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cyanocobalamin
+
Tannic acid
+
Zinc acetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DEPINAR | Armour Pharmaceutical | N-011208 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nitrotan | OTC monograph not final | 2013-07-26 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
348 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 19 | 97 | 98 | 8 | 28 | 242 |
| Invasive hydatidiform mole | D002820 | D39.2 | 1 | — | 2 | 1 | — | 4 | |
| Infertility | D007246 | EFO_0000545 | — | — | 1 | 1 | 1 | 3 | |
| Metrorrhagia | D008796 | HP_0100608 | N92.1 | — | — | — | 2 | — | 2 |
| Menstruation disturbances | D008599 | HP_0400007 | N91.5 | — | — | — | 1 | — | 1 |
| Menorrhagia | D008595 | N92.0 | — | — | — | 1 | — | 1 | |
| Medicated intrauterine devices | D007436 | — | — | — | 1 | — | 1 | ||
| Pharmacokinetics | D010599 | — | — | — | 1 | — | 1 | ||
| Sexuality | D019529 | — | — | — | 1 | — | 1 | ||
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | 1 | — | 1 |
Show 4 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Male breast neoplasms | D018567 | 1 | 8 | 4 | — | — | 13 | ||
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 2 | 5 | 1 | — | — | 8 |
| Triple negative breast neoplasms | D064726 | 2 | 4 | 2 | — | — | 8 | ||
| Ductal carcinoma breast | D018270 | — | 2 | 2 | — | 1 | 5 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 2 | 2 | — | — | 4 | |
| Fallopian tube neoplasms | D005185 | — | 2 | 2 | — | — | 4 | ||
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 2 | 1 | — | — | 3 |
| Prostatic neoplasms | D011471 | C61 | — | 2 | 1 | — | — | 3 | |
| Inflammatory breast neoplasms | D058922 | — | 1 | 1 | — | — | 2 | ||
| Neoplasm metastasis | D009362 | EFO_0009708 | 1 | — | 1 | — | — | 2 |
Show 25 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 4 | 3 | — | — | 2 | 9 | |
| Central nervous system neoplasms | D016543 | — | 5 | — | — | — | 5 | ||
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 3 | — | — | — | 3 |
| Covid-19 | D000086382 | U07.1 | — | 2 | — | — | — | 2 | |
| Glioblastoma | D005909 | EFO_0000515 | 1 | 1 | — | — | — | 2 | |
| Sarcoma | D012509 | — | 1 | — | — | 1 | 2 | ||
| Hot flashes | D019584 | — | 1 | — | — | 1 | 2 | ||
| Urinary bladder neoplasms | D001749 | C67 | — | 2 | — | — | — | 2 | |
| Glioma | D005910 | EFO_0000520 | — | 1 | — | — | — | 1 | |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 1 | — | — | — | 1 |
Show 29 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 1 | — | — | — | — | 1 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Gastrointestinal neoplasms | D005770 | C26.9 | 1 | — | — | — | — | 1 | |
| Barrett esophagus | D001471 | EFO_0000280 | K22.7 | 1 | — | — | — | — | 1 |
| Osteosarcoma | D012516 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | — | 1 | 1 | ||
| Depression | D003863 | F33.9 | — | — | — | — | 1 | 1 | |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 1 | 1 |
| Drug-related side effects and adverse reactions | D064420 | T88.7 | — | — | — | — | 1 | 1 | |
| Nutrition disorders | D009748 | EFO_0001069 | — | — | — | — | 1 | 1 | |
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | — | — | — | 1 | 1 |
| Cicatrix | D002921 | HP_0100699 | L90.5 | — | — | — | — | 1 | 1 |
| Survival analysis | D016019 | — | — | — | — | 1 | 1 | ||
| Genotype | D005838 | EFO_0000513 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TANNIC ACID |
| INN | — |
| Description | Tannic acid is a specific form of tannin, a type of polyphenol. Its weak acidity (pKa around 6) is due to the numerous phenol groups in the structure. The chemical formula for commercial tannic acid is often given as C76H52O46, which corresponds with decagalloyl glucose, but in fact it is a mixture of polygalloyl glucoses or polygalloyl quinic acid esters with the number of galloyl moieties per molecule ranging from 2 up to 12 depending on the plant source used to extract the tannic acid. Commercial tannic acid is usually extracted from any of the following plant parts: Tara pods (Caesalpinia spinosa), gallnuts from Rhus semialata or Quercus infectoria or Sicilian sumac leaves (Rhus coriaria).
|
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(OC[C@H]1O[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H](OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)[C@@H]1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1 |
Identifiers
| PDB | — |
| CAS-ID | 1401-55-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL506247 |
| ChEBI ID | 81066 |
| PubChem CID | 16129778 |
| DrugBank | DB09372 |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
ANO1
ANO1
Organism
Homo sapiens
Gene name
ANO1
Gene synonyms
DOG1, ORAOV2, TAOS2, TMEM16A
NCBI Gene ID
Protein name
anoctamin-1
Protein synonyms
anoctamin 1, calcium activated chloride channel, Ca2+-activated Cl- channel, calcium activated chloride channel, Discovered on gastrointestinal stromal tumors protein 1, oral cancer overexpressed 2, Oral cancer overexpressed protein 2, Transmembrane protein 16A, transmembrane protein 16A (eight membrane-spanning domains), Tumor-amplified and overexpressed sequence 2
Uniprot ID
Mouse ortholog
Ano1 (101772)
anoctamin-1 (Q99JK1)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,699 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10,446 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more